Apogee Therapeutics is like Sanofi or Eli Lilly, but focused on making their successful autoimmune and respiratory biologics significantly more convenient with less frequent dosing.

Imagine Apogee Therapeutics as a biotech company striving to produce 'extended-range' versions of blockbuster autoimmune drugs like Dupixent or Adbry.

Major Products of Apogee Therapeutics (APGE):

• APG777: An extended half-life monoclonal antibody targeting IL-13, primarily being developed for atopic dermatitis and potentially other inflammatory and immunological indications.
• APG808: An extended half-life monoclonal antibody targeting IL-4Rα, being developed for chronic obstructive pulmonary disease.
• APG990: A development candidate utilizing advanced antibody engineering to target OX40L, initially for atopic dermatitis.
• APG222: A development candidate designed to simultaneously inhibit both IL-13 and OX40L, initially for atopic dermatitis and other inflammatory and immunological indications.

Apogee Therapeutics (APGE) is a biotechnology company focused on the development of biologics for the treatment of inflammatory and immunology indications. As described in the background, the company is in the research and development phase, with its lead programs, APG777 and APG808, in preclinical or early clinical development stages (e.g., Phase 1 clinical trial for APG777 anticipated in the second half of 2023).

Given its stage of development, Apogee Therapeutics does not currently have major customers as it is not yet commercializing or selling any approved pharmaceutical products. The company's focus is on conducting clinical trials and advancing its pipeline of drug candidates. Therefore, it does not sell to other companies or directly to individuals at this time.

Michael Henderson, MD, Chief Executive Officer

Michael Henderson joined Apogee Therapeutics in September 2022, also serving as a Board member. He is a seasoned biotechnology industry leader with expertise in business leadership, drug development, and commercial strategy. Prior to Apogee, he spearheaded the creation of over 20 companies, launched 40 drug development programs, and led two teams to FDA approvals. He previously served as Chief Business Officer of BridgeBio Pharma, Inc., where he was responsible for corporate strategy, identifying and investing in new technologies, and managing business development and operations. He also held leadership positions for several prominent subsidiary companies of BridgeBio. Dr. Henderson co-founded PellePharm, Inc. and worked at McKinsey & Company. He currently serves on the Board of Spyre Therapeutics.

Jane Pritchett Henderson, Chief Financial Officer

Jane Pritchett Henderson has served as Chief Financial Officer of Apogee Therapeutics since January 2023. She possesses over 34 years of experience in growing public and private biopharmaceutical companies and investment banking, coupled with extensive board experience. Prior to Apogee, Ms. Henderson was Chief Financial Officer and Chief Business Officer at Invivyd Therapeutics (formerly Adagio Therapeutics), where she led the company's Series C crossover financing and subsequent IPO. She has held executive leadership roles in finance and corporate development at several biotechnology companies, including Turnstone Biologics, Voyager Therapeutics, Kolltan Pharmaceuticals (acquired by Celldex), and ISTA Pharmaceuticals (acquired by Bausch + Lomb). Ms. Henderson also has nearly 20 years of experience in healthcare investment banking, executing over 95 mergers and acquisitions and financing deals at firms such as HSBC Holdings plc, Canadian Imperial Bank of Commerce, Lehman Brothers, and Salomon Brothers. Her background demonstrates a consistent pattern of managing companies that have received private equity or venture capital backing, undergone significant financing rounds, and engaged in M&A activities. She serves on the board of directors for Akero Therapeutics, IVERIC bio, and Ventus Therapeutics.

Carl Dambkowski, MD, Chief Medical Officer

Carl Dambkowski serves as the Chief Medical Officer of Apogee Therapeutics.

Rebecca Dabora, PhD, Chief Technology Officer

Rebecca Dabora brings over 30 years of expertise in chemistry, manufacturing, and controls (CMC) to Apogee Therapeutics, with deep experience in developing clinical and commercial-stage biopharmaceutical products. She has held executive roles leading technical operations for companies including Invivyd, Aspyrian Therapeutics, and SwanBio Therapeutics. Her career also includes positions at Merck & Co. and Biogen, Inc., where she worked in process development and played a key role in the commercialization of Avonex®.

Jeff S. Hartness, Chief Commercial Officer

Jeff S. Hartness was appointed Chief Commercial Officer in September 2024. He brings more than 25 years of experience in the biotech industry, specializing in product launches, market access strategy, pricing, and policy. Prior to joining Apogee, Mr. Hartness spent eight years at Bausch Health in roles of increasing responsibility, most recently as Executive Vice President on the Global Executive Leadership Team, overseeing market access, commercial operations, policy, and government affairs, as well as serving as General Manager of the Neurology portfolio and Generics businesses. He also previously held the position of Sr. Vice President and Head of Strategic Account Management, Pricing, Contracting, and Distribution, where he was responsible for planning and implementing payer and Go-to-Market strategies.

1. Clinical Development and Regulatory Approval Risk

   Apogee Therapeutics' business is entirely dependent on the successful outcome of its preclinical studies and clinical trials, and the subsequent regulatory approval of its product candidates. All of the company's programs, APG777, APG808, APG990, and APG222, are in very early stages of development, with APG777 anticipated to begin a Phase 1 clinical trial in the second half of 2023, and APG808 still in the development candidate nomination phase. There is a high risk that these product candidates will not prove safe or effective, or may not demonstrate the anticipated improvements in dosing frequency over existing therapies, potentially failing at any stage of development or not receiving the necessary regulatory approvals, which would severely impact the company's prospects.

2. Competition

   The biotechnology industry and the specific therapeutic areas Apogee Therapeutics is targeting (atopic dermatitis, COPD, and other I&I indications) are highly competitive. The company aims to "overcome limitations of existing therapies," indicating the presence of established treatments and other companies developing new ones. Even if Apogee's product candidates are successfully developed, they will face significant competition from currently approved biologics and other therapies, as well as new treatments that may emerge, which could limit their market potential and commercial success.

3. Reliance on Additional Funding

   As a newly incorporated company (June 2023) with no prior business operations, no approved products, and no revenue, Apogee Therapeutics is entirely dependent on its ability to raise substantial additional capital to fund its extensive and costly research and development activities, including ongoing preclinical studies and clinical trials. There is no guarantee that the company will be able to obtain sufficient funding on acceptable terms, or at all, which could force it to delay, reduce, or abandon its development programs and operations.

The addressable markets for Apogee Therapeutics' main products are as follows:

• APG777 (Atopic Dermatitis): This product targets atopic dermatitis (AD). The addressable market in the United States, France, Germany, Italy, Japan, Spain, and the United Kingdom consists of approximately 40 million adults and 18 million children with AD. Of these, 40% have moderate-to-severe disease.
• APG808 (Chronic Obstructive Pulmonary Disease - COPD): This product targets chronic obstructive pulmonary disease (COPD). The addressable market in the United States, France, Germany, Italy, Japan, Spain, and the United Kingdom includes approximately 32 million adults 40 years of age and older with COPD.

Expected Drivers of Future Revenue Growth for Apogee Therapeutics (APGE)

For Apogee Therapeutics (APGE), a clinical-stage biotechnology company with no currently commercialized products, future revenue growth over the next 2-3 years will primarily be driven by key pipeline advancements and the resulting potential for strategic partnerships or financing events. These drivers increase the company's valuation and can lead to non-dilutive funding or milestone payments.

1. Positive Clinical Data and Progression of APG777: The anticipated release of initial subcutaneous (SQ) pharmacokinetic (PK) and safety data from the Phase 1 clinical trial of APG777 in mid-2024 will be a significant de-risking event. Following positive data, the expected filing of an Investigational New Drug (IND) application and initiation of a Phase 2 trial for APG777 in atopic dermatitis (AD) will further validate the program. This progression is crucial for attracting potential partners or securing additional financing that could generate revenue through upfront payments or equity investments.

2. Advancement of APG808 into Clinical Development: The nomination of a development candidate for APG808, targeting chronic obstructive pulmonary disease (COPD), in 2023, followed by the intended filing of an IND or foreign equivalent to initiate clinical trials, represents another key pipeline catalyst. The commencement of human clinical trials for APG808 would increase the program's value, making it more attractive for strategic collaborations or funding opportunities that could contribute to future revenue streams.

3. Pipeline Expansion through APG990 Development Candidate Nomination: The expected nomination of a development candidate for APG990, an OX40L inhibitor for AD, in 2024, demonstrates the breadth and ongoing progression of Apogee's earlier-stage pipeline. While earlier in development, successful preclinical advancement and candidate nomination can enhance the company's overall valuation and attractiveness for early-stage partnerships or research agreements, providing potential revenue.

4. Strategic Partnerships and Licensing Agreements: As a pre-commercial entity, a primary driver of future revenue growth for Apogee Therapeutics will be its ability to secure strategic partnerships or licensing agreements for its differentiated biologic programs, particularly APG777 and APG808. Positive clinical data and successful advancement of these programs into later stages of development would be strong catalysts for attracting partners, potentially leading to significant upfront payments, research funding, and future milestone payments, all of which would be recognized as revenue for the company.

Share Issuance

• Apogee Therapeutics completed its initial public offering (IPO) on July 13, 2023, raising approximately $300.05 million by issuing 17.65 million shares at $17.00 per share.
• In March 2024, the company closed a public offering that generated approximately $483.0 million in gross proceeds from the sale of 7,790,321 shares of common stock at $62.00 per share.
• Another public offering in October 2025 resulted in approximately $345 million in gross proceeds (net proceeds of approximately $323.3 million) from the sale of 8,048,782 shares of common stock and pre-funded warrants.

Inbound Investments

• Apogee Therapeutics completed an oversubscribed $149 million Series B financing round in December 2022.
• The company launched with $169 million in total capital raised, which included its Series A investment from founding investors.

Capital Expenditures

• Apogee Therapeutics' capital expenditures for the last 12 months, as of November 2025, were -$5.84 million.
• In Q4 2025, Apogee Therapeutics invested $62K in capital expenditures.
• Proceeds from public offerings are intended to fund capital expenditures, among other activities, primarily to support preclinical studies, clinical trials, manufacturing, and research and development for its antibody programs.